Moderna Initiates Construction of First China-Based Pharmaceutical Plant in Shanghai
S-based mRNA specialist, Moderna (NASDAQ: MRNA), has commenced construction on its inaugural pharmaceutical facility in...
Senti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China
Senti Biosciences Inc., (NASDAQ: SNTI), a San Francisco-based biotech company, has announced a strategic collaboration...
Eisai Partners with Shanghai Pharmaceuticals for Alzheimer’s Drug Leqembi in China
Eisai (TYO: 4523), a Japan-headquartered pharmaceutical company, has entered into a significant partnership with Shanghai...
Bayer and Shanghai Pharmaceuticals Launch Co.Lab to Incubate Life Sciences Innovation in China
Bayer, the Germany-headquartered multinational pharmaceutical and life sciences company (ETR: BAYN), has entered into a...
Abbisko Therapeutics Receives FDA Approval for Phase I Study of FGFR4 Inhibitor ABSK012
Shanghai-based biotech company Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...
Fosun Pharmaceutical and Insightec Collaborate on Non-Invasive Brain Treatment Technology
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced a strategic partnership with Israel-based...
9th National Volume-Based Procurement Round Results in 70% Price Reduction for 41 Drugs
The results of the 9th round of China’s national volume-based procurement (VBP) program have been...
Qingdao’s Raise Care Secures Over RMB 100 Million in Series B Financing Led by CITIC Capital
Qingdao-based Raise Care has reportedly secured upwards of RMB 100 million (USD 13.7 million) in...
Chengdu Kanghong Pharmaceutical’s KH629 Receives FDA Approval for NASH Clinical Trial
Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a China-based pharmaceutical company, has announced that...
FibroGen Inc. Reports 155% YOY Sales Increase in Q3 2023 Financial Results
US-based biotechnology company FibroGen Inc., (NASDAQ: FGEN) has reported its financial results for the third...
GSK Acquires Global Rights to Janssen’s Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal
GlaxoSmithKline (GSK; NYSE: GSK) has announced the acquisition of global rights to the hepatitis B...
Gilead Sciences and Arcus Biosciences Announce Positive Phase II Data for Domvanalimab Combination Therapy
Gilead Sciences (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have this week released preliminary data...
Clover Biopharmaceuticals Submits Market Filing for Seasonal Influenza Vaccine in Brazil
China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced the submission of a market filing for...
WuXi XDC Aims for HKEX Listing with IPO of 178.4 Million Shares
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
Boehringer Ingelheim’s Aldosterone Synthase Inhibitor BI 690517 Shows Promise in CKD Phase II Trial
Germany-based Boehringer Ingelheim (BI) has published the results of a Phase II trial for its...
Sun Yat-sen Memorial Hospital Partners with Siemens Healthineers on Metaverse Visualization Surgery
China’s Sun Yat-sen Memorial Hospital, affiliated with Sun Yat-sen University, has entered into a strategic...
Danone Enters China’s Adult FSMP Market with Local Production of Fortimel
France-based food company Danone has revealed its strategic plans to enter the adult foods for...
SciClone Pharmaceuticals Secures Exclusive Rights to Menarini Group’s Orserdu in China
China’s SciClone Pharmaceuticals Inc., (HKG: 6600) has entered into a licensing and cooperation agreement with...
RinuaGene Receives US FDA IND Approval for HPV-Associated Tumor mRNA Vaccine RG002
RinuaGene, a leading mRNA specialist headquartered in Suzhou, has announced that it has received Investigational...
Enhertu Receives Priority Review Status for HER2-Positive Gastric Cancer Treatment in China
The Center for Drug Evaluation (CDE) website has indicated that Enhertu (trastuzumab deruxtecan), a HER2-targeted...